UNIVERSAL HEALTH SERV 'B' 
By NEW YORK, January 6, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Limited (NYSE: TEVA), Illumina Inc. (NASDAQ: ILMN), Becton, Dickinson and Company (NYSE: BDX), Novartis AG (NYSE: NVS), and Universal Health Services Inc. (NYSE: UHS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Teva Pharmaceutical Industries Limited Research Report
On December 31, 2013, Teva Pharmaceutical Industries Limited's (Teva) stock declined 0.02%, ending the day at $40.08. Over the previous three trading sessions, shares of Teva increased 0.93%, compared to the Dow Jones Industrial Average which also increased 0.59% during the same period. The Full Research Report on Teva Pharmaceutical Industries Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/e3a3_TEVA
--
Illumina Inc. Research Report
On December 23, 2013, Illumina Inc. (Illumina) announced the live webcast of the Company's presentations for two upcoming events. Illumina will webcast its presentation at the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California on January 14, 2014. According to the Company, the live webcast is slated to start at 8:30 a.m. PT, featuring a presentation by Jay Flatley, CEO of the Company. Illumina informed that it will also hold an Investor Day in San Francisco on January 16, 2014, starting at 1:00 p.m. PT, which will also be webcast live, highlighting updates on the Company's businesses and markets. Illumina noted that only invited attendees can take part at this event. However, interested parties can access the webcast via the Investor Relations section of Illumina's website under the "Company" tab. The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/3cf2_ILMN
--
Becton, Dickinson and Company Research Report
On December 31, 2013, Becton, Dickinson and Company (BD) stock declined 0.10%, ending the day at $110.49. Over the previous three trading sessions, shares of BD increased 0.35%, compared to the Dow Jones Industrial Average which also increased 0.59% during the same period. The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/0175_BDX
--
Novartis AG Research Report
On December 18, 2013, Sandoz, generic pharmaceuticals division of Novartis AG (Novartis), declared that it was granted Danish marketing authorization for AirFluSal(R) Forspiro(R), a new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval is in accordance with the completion of EU decentralized procedures (DCP) for Denmark and seven other EU countries. AirFluSal(R) Forspiro(R) provides the tried and tested fusion of salmeterol (a long-acting inhaled ss2-agonist) and fluticasone (an inhaled corticosteroid) in a new inhalation device. Jeff George, Global Head of Sandoz, commented, "The first approval of AirFluSal(R) Forspiro(R) is a key element of our strategy to introduce differentiated generic medicines. This innovative new respiratory device underscores Novartis's commitment to asthma and COPD patients and further strengthens Sandoz' global leadership in differentiated products, which comprised 43 percent of our sales in 2012." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/9b6d_NVS
--
Universal Health Services Inc. Research Report
On December 31, 2013, Universal Health Services Inc. (UHS) stock increased 1.35%, ending the day at $81.26. Over the previous three trading sessions, shares of UHS increased 0.83%, compared to the Dow Jones Industrial Average which also increased 0.59% during the same period. The Full Research Report on Universal Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/7d77_UHS
----
EDITOR NOTES:
1) This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2) Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or omissions, please notify
us below.
3) This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the investing
public.
4) If you wish to have your company covered in more detail by our team, or wish
to learn more about our services, please contact us at
pubco@EquityNewsNetwork.com.
5) For any urgent concerns or inquiries, please contact us at
compliance@EquityNewsNetwork.com.
6) Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to research@EquityNewsNetwork.com for
consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
